BRAF inhibitor unveils its potential against advanced melanoma
- PMID: 20951940
- DOI: 10.1016/j.ccr.2010.10.001
BRAF inhibitor unveils its potential against advanced melanoma
Abstract
Unresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, the discovery of BRAF-activating mutations in approximately 50% of human melanomas has provided an attractive therapeutic target. Here, we discuss two recent publications focusing on the mutant BRAF kinase inhibitor PLX4032 that validate oncogene-targeted melanoma therapy.
Copyright © 2010 Elsevier Inc. All rights reserved.
Comment on
-
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.Clin Cancer Res. 2008 Aug 1;14(15):4836-42. doi: 10.1158/1078-0432.CCR-07-4123. Clin Cancer Res. 2008. PMID: 18676756 Clinical Trial.
-
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.Nature. 2010 Sep 30;467(7315):596-9. doi: 10.1038/nature09454. Nature. 2010. PMID: 20823850 Free PMC article. Clinical Trial.
Similar articles
-
Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.Hum Pathol. 2005 May;36(5):486-93. doi: 10.1016/j.humpath.2005.03.015. Hum Pathol. 2005. PMID: 15948115
-
BRAF kinase in melanoma development and progression.Expert Rev Mol Med. 2008 Feb 18;10:e6. doi: 10.1017/S1462399408000604. Expert Rev Mol Med. 2008. PMID: 18279546 Review.
-
Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.Oncogene. 2003 Dec 18;22(58):9217-24. doi: 10.1038/sj.onc.1206909. Oncogene. 2003. PMID: 14681681
-
The MAPK pathway in melanoma.Curr Opin Oncol. 2008 Mar;20(2):183-9. doi: 10.1097/CCO.0b013e3282f5271c. Curr Opin Oncol. 2008. PMID: 18300768 Review.
-
Inducible BRAF suppression models for melanoma tumorigenesis.Methods Enzymol. 2008;439:25-38. doi: 10.1016/S0076-6879(07)00403-X. Methods Enzymol. 2008. PMID: 18374154
Cited by
-
Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma.BMC Cancer. 2014 Aug 29;14:630. doi: 10.1186/1471-2407-14-630. BMC Cancer. 2014. PMID: 25168062 Free PMC article.
-
Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma.Cancer Res. 2012 Oct 1;72(19):4909-19. doi: 10.1158/0008-5472.CAN-12-2194. Epub 2012 Aug 3. Cancer Res. 2012. PMID: 22865454 Free PMC article.
-
Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells.Cancers (Basel). 2024 Jan 22;16(2):470. doi: 10.3390/cancers16020470. Cancers (Basel). 2024. PMID: 38275910 Free PMC article. Review.
-
New 1,2,3-triazole/1,2,4-triazole hybrids linked to oxime moiety as nitric oxide donor selective COX-2, aromatase, B-RAFV600E and EGFR inhibitors celecoxib analogs: design, synthesis, anti-inflammatory/anti-proliferative activities, apoptosis and molecular modeling study.J Enzyme Inhib Med Chem. 2023 Dec;38(1):2290461. doi: 10.1080/14756366.2023.2290461. Epub 2023 Dec 7. J Enzyme Inhib Med Chem. 2023. PMID: 38061801 Free PMC article.
-
Recent progress in targeting cancer.Aging (Albany NY). 2011 Dec;3(12):1154-62. doi: 10.18632/aging.100421. Aging (Albany NY). 2011. PMID: 22228887 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials